矛盾的 AKT：探索 PI3K/AKT/mTOR 靶向疗法的前景与挑战。

{"title":"矛盾的 AKT：探索 PI3K/AKT/mTOR 靶向疗法的前景与挑战。","authors":"Gennie L Parkman, Sheri L Holmen","doi":"10.33696/cancerimmunol.6.089","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 3","pages":"92-99"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460539/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies.\",\"authors\":\"Gennie L Parkman, Sheri L Holmen\",\"doi\":\"10.33696/cancerimmunol.6.089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73633,\"journal\":{\"name\":\"Journal of cancer immunology\",\"volume\":\"6 3\",\"pages\":\"92-99\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460539/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33696/cancerimmunol.6.089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/cancerimmunol.6.089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}